Last reviewed 2026-05-14 · How we verify

NNC 0172-0000-2021

Novo Nordisk A/S · Phase 1 active Small molecule

NNC 0172-0000-2021 is a Small molecule drug developed by Novo Nordisk A/S. It is currently in Phase 1 development.

At a glance

Generic name	NNC 0172-0000-2021
Sponsor	Novo Nordisk A/S
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NNC 0172-0000-2021 CI brief — competitive landscape report
NNC 0172-0000-2021 updates RSS · CI watch RSS
Novo Nordisk A/S portfolio CI

Frequently asked questions about NNC 0172-0000-2021

What is NNC 0172-0000-2021?

NNC 0172-0000-2021 is a Small molecule drug developed by Novo Nordisk A/S.

Who makes NNC 0172-0000-2021?

NNC 0172-0000-2021 is developed by Novo Nordisk A/S (see full Novo Nordisk A/S pipeline at /company/novo-nordisk).

What development phase is NNC 0172-0000-2021 in?

NNC 0172-0000-2021 is in Phase 1.

Manufacturer: Novo Nordisk A/S — full pipeline
Compare: NNC 0172-0000-2021 vs similar drugs
Pricing: NNC 0172-0000-2021 cost, discount & access